Profil

Onesti Concetta Elisa

See author's contact details
Main Referenced Co-authors
Marchetti, Paolo (43)
Botticelli, Andrea (25)
Mazzuca, Federica (25)
Falcone, Rosa (21)
Roberto, Michela (19)
Main Referenced Keywords
Humans (2); oncology (2); abemaciclib (1); Adult (1); Algorithms (1);
Main Referenced Disciplines
Oncology (68)

Publications (total 68)

The most downloaded
509 downloads
Romiti, A., ONESTI, C. E., Roberto, M., Barucca, V., Tomao, S., D'Antonio, C., Durante, V., Milano, A., Falcone, R., Di Rocco, R., Righini, R., & Marchetti, P. (March 2015). Continous, low-dose capecitabine for patients with recurrent colorectal cancer. Medical Oncology, 32 (3), 54. doi:10.1007/s12032-015-0496-z https://hdl.handle.net/2268/217580

The most cited

158 citations (Scopus®)

Vecchione, A., Belletti, B., Lovat, F., Volinia, S., Chiappetta, G., Giglio, S., Sonego, M., Cirombella, R., ONESTI, C. E., Pellegrini, P., Califano, D., Pignata, S., Losito, S., Canzonieri, V., Sorio, R., Alder, H., Wernicke, D., Stoppacciaro, A., Baldassarre, G., & Croce, C. M. (June 2013). A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 110 (24), 9845-50. doi:10.1073/pnas.1305472110 https://hdl.handle.net/2268/217588

Schettini, F., Venturini, S., Giuliano, M., Lambertini, M., Pinato, D. J., Onesti, C. E., De Placido, P., Harbeck, N., Lüftner, D., Denys, H., Van Dam, P., Arpino, G., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., ... Generali, D. (December 2022). Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. Cancer Treatment Reviews, 111, 102468. doi:10.1016/j.ctrv.2022.102468
Peer Reviewed verified by ORBi

ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., ... Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571
Peer reviewed

Poncin, A., Onesti, C. E., JOSSE, C., Boulet, D., Thiry, J., Bours, V., & Jerusalem, G. (August 2021). Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines, 9 (9), 1087. doi:10.3390/biomedicines9091087
Peer Reviewed verified by ORBi

Onesti, C. E., & Jerusalem, G. (2021). CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Review of Anticancer Therapy, 21 (3), 283-298. doi:10.1080/14737140.2021.1852934
Peer Reviewed verified by ORBi

ONESTI, C. E., Tagliamento, M., Curigliano, G., Harbeck, N., Bartsch, R., Wildiers, H., Tjan-Heijnen, V., Martin, M., Rottey, S., Generali, D., Campone, M., Cristofanilli, M., Pusztai, L., Peeters, M., Berchem, G., Cortes, J., Ruhstaller, T., Ciruelos, E., Rugo, H. S., & Jerusalem, G. (2021). Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO global oncology, 7, 162-172. doi:10.1200/GO.20.00589
Peer Reviewed verified by ORBi

Schettini, F., Giuliano, M., Lambertini, M., Bartsch, R., Pinato, D. J., ONESTI, C. E., Harbeck, N., Rottey, S., Van Dam, P. A., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., Tjan-Heijnen, V. C. G., Cortes, J., Locci, M., ... Generali, D. (2021). Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 13 (17), 4421. doi:10.3390/cancers13174421
Peer reviewed

Onesti, C. E., JOSSE, C., Boulet, D., Bours, V., & JERUSALEM, G. (2020). High plasmatic levels of IL-4 and IL- 13 are associated with recurrence and worse survival in breast cancer. Tumori Journal.
Peer Reviewed verified by ORBi

ONESTI, C. E., JOSSE, C., Beaumecker, B., Boulet, D., Thiry, J., BOURS, V., & JERUSALEM, G. (2020). The relative eosinophil count in breast cancer as an emerging prognostic biomarker. European Journal of Cancer. doi:10.1016/S0959-8049(20)30766-8
Peer reviewed

Carneiro, A., Amaral, T., Brandao, M., Scheffler, M., Boj, K., Ferrara, R., Jalving, M., Lo Russo, G., Marquez-Rodas, I., Matikas, A., Mezquita, L., Morgan, G., ONESTI, C. E., Pilotto, S., Saloustros, E., & Trapani, D. (2020). Disparities in access to oncology clinical trials in Europe in the period 2009-2019. Annals of Oncology.
Peer Reviewed verified by ORBi

JERUSALEM, G., ONESTI, C. E., Generali, D., Harbeck, N., Wildiers, H., Curigliano, G., Campone, M., Tjan-Heijnen, V., Martin, M., Cristofanilli, M., Pusztai, L., Bartsch, R., Peeters, M., Berchem, G., Tagliamento, M., Cortès, J., Ruhsthaller, T., Ciruelos, E., Rottey, S., & Rugo, H. (2020). Expected medium and long term impact of the COVID-19 outbreak in oncology. Annals of Oncology.
Peer Reviewed verified by ORBi

ONESTI, C. E., Rugo, H. S., Generali, D., Peeters, M., Zaman, K., Wildiers, H., Harbeck, N., Martin, M., Cristofanilli, M., Cortes, J., Tjan-Heijnen, V., Hurvitz, S. A., Berchem, G., Tagliamento, M., Campone, M., Bartsch, R., De Placido, S., Puglisi, F., Rottey, S., ... JERUSALEM, G. (August 2020). Oncological care organisation during COVID-19 outbreak. ESMO Open, 5. doi:10.1136/esmoopen-2020-000853
Peer Reviewed verified by ORBi

ONESTI, C. E., JOSSE, C., Boulet, D., Thiry, J., Beaumecker, B., BOURS, V., & JERUSALEM, G. (2020). Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. Oncoimmunology. doi:10.1080/2162402X.2020.1761176
Peer Reviewed verified by ORBi

ONESTI, C. E., SCHROEDER, H., RORIVE, A., SAUTOIS, B., LECOCQ, M., Goffin, M., GONNE, E., COLLINGE, A., NICOLAERS, L., WERA, O., Catot, A., LOLY, C., PAULUS, A., SIBILLE, A., LOUSBERG, L., Troisfontaine, F., COLLIGNON, J., GENNIGENS, C., FRERES, P., & JERUSALEM, G. (2020). How do oncological patients perceive the Covid-19 (SARS-CoV-2) pandemic ? Experience from CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain.

LECOCQ, M., ONESTI, C. E., SCHROEDER, H., RORIVE, A., Goffin, M., GONNE, E., SAUTOIS, B., Catot, A., WERA, O., NICOLAERS, L., COLLINGE, A., Collignon, J., FRERES, P., POLUS, M., DUYSINX, B., VAILLANT, F., GENNIGENS, C., MARCHAL, N., PONCIN, A., & JERUSALEM, G. (2020). Risk of SARS-CoV-2 infection and outcome after infection : Experience from the day-care unit at CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain.

ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., Poulet, C., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome. Annals of Oncology.
Peer Reviewed verified by ORBi

ONESTI, C. E., FRERES, P., & JERUSALEM, G. (2019). Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment. Journal of Thoracic Disease. doi:10.21037/jtd.2018.12.47
Peer Reviewed verified by ORBi

Onesti, C. E., Iacono, D., Angelini, S., Mazzotta, M., Giusti, R., Lauro, S., & Marchetti, P. (2019). Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis. Anti-Cancer Drugs, 30 (2), 201-204. doi:10.1097/CAD.0000000000000699
Peer Reviewed verified by ORBi

ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy. Journal of Translational Medicine, 17, 239. doi:10.1186/s12967-019-1984-2
Peer Reviewed verified by ORBi

ONESTI, C. E., JOSSE, C., Poncin, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (2018). Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget. doi:10.18632/oncotarget.26120
Peer Reviewed verified by ORBi

ONESTI, C. E., JOSSE, C., PONCIN, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (13 September 2018). Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment [Paper presentation]. GIGA-Cancer Day 2018 / EDT-Cancerology Vascular landscape and (pre)metastatic niche in cancer biology.

Roberto, M., Botticelli, A., Strigari, L., Ghidini, M., ONESTI, C. E., Ratti, M., Benzoni, I., Pizzo, C., Falcone, R., Lomiento, D., Donida, B. M., Totaro, L., Mazzuca, F., & Marchetti, P. (19 June 2018). Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. Medical Oncology, 35 (7), 111. doi:10.1007/s12032-018-1166-8
Peer Reviewed verified by ORBi

Botticelli, A., Cerbelli, B., Lionetto, L., Zizzari, I., Pisano, A., Roberto, M., ONESTI, C. E., Di Pietro, F., Napoletano, C., Pizzuti, L., Vici, P., D'Amati, G., Mazzuca, F., Simmaco, M., Nuti, P., & Marchetti, P. (2018). The key role of kynurenine in antiPD-1 failure. Cancer Research.
Peer Reviewed verified by ORBi

Milano, A., Mazzetta, F., Valente, S., Ranieri, D., Leone, L., Botticelli, A., ONESTI, C. E., Lauro, S., Raffa, S., Torrisi, M. R., & Marchetti, P. (2018). Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. Analytical Cellular Pathology. doi:10.1155/2018/3506874
Peer Reviewed verified by ORBi

Occhipinti, M., Falcone, R., ONESTI, C. E., & Marchetti, P. (2018). Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. Drug Safety - Case Reports, 5 (1), 12. doi:10.1007/s40800-018-0078-z
Peer Reviewed verified by ORBi

Mazzuca, F., ONESTI, C. E., Roberto, M., Di Girolamo, M., Botticelli, A., Begini, P., Strigari, L., Marchetti, P., & Mazzuca, F. (2018). Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget. doi:10.18632/oncotarget.25394
Peer Reviewed verified by ORBi

Botticelli, A., Putignani, L., Zizzari, I., Del Chierico, F., Reddel, S., Di Pietro, F., Quagliarello, ONESTI, C. E., Giusti, R., Mazzuca, F., Nuti, M., & Marchetti, P. (2018). Changes of microbiome profile during nivolumab treatment in NSCLC patients. Journal of Clinical Oncology, 36 (suppl), 15020.
Peer Reviewed verified by ORBi

Occhipinti, M., Falcone, R., ONESTI, C. E., Botticelli, A., Mazzuca, F., Marchetti, P., & Lauro, S. (November 2017). Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. Journal of Thoracic Disease, 9 (11), 985-E989. doi:10.21037/jtd.2017.09.74
Peer Reviewed verified by ORBi

Botticelli, A., ONESTI, C. E., Zizzari, I., Cerbelli, B., Sciattella, P., Occhipinti, M., Roberto, M., Di Pietro, F., Bonifacino, A., Ghidini, M., Vici, P., Pizzuti, L., Napoletano, C., Strigari, L., D'Amati, G., Mazzuca, F., Nuti, M., & Marchetti, P. (November 2017). The sexist behaviour of immune checkpoint inhibitors in cancer therapy? Oncotarget, 8 (59), 99336-99346. doi:10.18632/oncotarget.22242
Peer Reviewed verified by ORBi

Occhipinti, M., Botticelli, A., ONESTI, C. E., Ghidini, M., Righini, R., Pizzo, C., Milano, A., Tomasello, G., Di Pietro, F. R., Toppo, L., Ratti, M., Passalacqua, R., Marchetti, P., & Mazzuca, F. (October 2017). Treatment and outcome for small bowel adenocarcinoma (SBA): a real life experience of two Italian centres. Annals of Oncology, 28 (Suppl 6). doi:10.1093/annonc/mdx425.022
Peer Reviewed verified by ORBi

Botticelli, A., ONESTI, C. E., Strigari, L., Occhipinti, M., Di Pietro, F., Cerbelli, B., Petremolo, A., Anselmi, E., Macrini, S., Roberto, M., Falcone, R., Lionetto, L., Borro, M., Milano, A., Gentile, G., Simmaco, M., Marchetti, P., & Mazzuca, F. (June 2017). A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. Anti-Cancer Drugs, 28 (5), 551-556. doi:10.1097/CAD.0000000000000492
Peer Reviewed verified by ORBi

Angelini, S., Botticelli, A., ONESTI, C. E., Giusti, R., Sini, V., Durante, V., Strigari, L., Gentile, G., Cerbelli, B., Pellegrini, P., Sgroi, V., Occhipinti, M., Di Pietro, F., Rossi, A., Simmaco, M., Mazzuca, F., & Marchetti, P. (May 2017). Pharmacogenomics Approach to Toxicity in Breast Cancer Patients Treated with Taxanes. Anticancer Research, 37 (5), 2633-2639. doi:10.21873/anticanres.11610
Peer Reviewed verified by ORBi

ONESTI, C. E., Botticelli, A., La Torre, M., Borro, M., Gentile, G., Romiti, A., Lionetto, L., Petremolo, A., Occhipinti, M., Roberto, M., Falcone, R., Simmaco, M., Marchetti, P., & Mazzuca, F. (March 2017). 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. Anti-Cancer Drugs, 28 (3), 322-326. doi:10.1097/CAD.0000000000000453
Peer Reviewed verified by ORBi

Roberto, M., Romiti, A., Botticelli, A., Mazzuca, F., Lionetto, L., Gentile, G., Paris, I., Falcone, R., Bassanelli, M., Di Pietro, F., ONESTI, C. E., Anselmi, E., Macrini, S., Simmaco, M., & Marchetti, P. (February 2017). Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. European Journal of Clinical Pharmacology, 73 (2), 157-164. doi:10.1007/s00228-016-2160-8
Peer Reviewed verified by ORBi

Borro, M., Botticelli, A., Mazzuca, F., ONESTI, C. E., Gentile, G., Romiti, A., Cerbelli, B., Mazzotti, E., Marchetti, L., Lionetto, L., Simmaco, M., & marchetti, P. (February 2017). Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. Oncotarget, 8 (8), 14050-14057. doi:10.18632/oncotarget.12571
Peer Reviewed verified by ORBi

Toppo, L., Liguigli, W., Senti, C., Tomasello, G., Ghidini, M., Ratti, M., Botticelli, A., ONESTI, C. E., Di Pietro, F., Pizzo, C., Panni, S., Curti, A., & Passalacqua, R. (2017). Presence of bone metastases(BM) at diagnosis is associated with poor prognosis and coagulation disorders (CD) in patients (pts) with advanced gastric cancer (AGC). Journal of Clinical Oncology, 35.
Peer Reviewed verified by ORBi

ONESTI, C. E., Botticelli, A., Occhipinti, M., Di Pietro, F., Zizzari, I., Napoletano, C., Nuti, M., Lauro, S., Mazzuca, F., & Marchetti, P. (2017). Early onset of endocrine alterations during PD-1 blockade in advanced NSCLC patients. Annals of Oncology, 28S (Suppl 2).
Peer Reviewed verified by ORBi

Ghidini, M., Botticelli, A., Donida, B. M., Strigari, L., ONESTI, C. E., Ratti, M., Pizzo, C., Aldighieri, F., Toppo, L., Ranieri, V., Occhipinti, M., Senti, C., Tanzi, G., Mazzuca, F., Marchetti, P., Martinotti, M., Passalaqua, R., Tomasello, G., & Rovatti, M. (2017). Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers. Journal of Clinical Oncology, 35.
Peer Reviewed verified by ORBi

Nuti, M., Zizzari, I., Napoletano, C., Botticelli, A., Calabro, F., Gelibter, A., Rughetti, A., Ugolini, A., Ruscito, I., Mazzuca, F., Rahimi, H., ONESTI, C. E., Cortesi, E., & Marchetti, P. (2017). Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients. Journal of Clinical Oncology, 35.
Peer Reviewed verified by ORBi

Botticelli, A., Cerbelli, B., Pernazza, A., ONESTI, C. E., Sciattella, P., Costarelli, L., Monti, M., Cmpagna, D., Mazzuca, F., Fortunato, L., Marchetti, P., & D'Amati, G. (2017). PD-L1 expression in TNBC: A predictive biomarker of response to neoadjuvant chemotherapy? Annals of Oncology, 28 (Suppl 5), 30.
Peer Reviewed verified by ORBi

D'Antonio, C., Lombardini, A., ONESTI, C. E., Falcone, R., Romiti, A., Lombardi, M., Lauro, S., & Marchetti, P. (December 2016). A rare case of palatin tonsillar metastasis from small cell lung cancer. Translational Lung Cancer Research, 5 (6), 709-711. doi:10.21037/tlcr.2016.11.07
Peer Reviewed verified by ORBi

Falcone, R., Roberto, M., D'Antonio, C., Romiti, A., Milano, A., ONESTI, C. E., Marchetti, P., & Fais, S. (2016). High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art. Digestive and Liver Disease. doi:10.1016/j.dld.2016.08.126
Peer Reviewed verified by ORBi

ONESTI, C. E., Iacono, D., Angelini, S., Lauro, S., Mazzotta, M., Occhipinti, M. A., Giusti, R., & Marchetti, P. (December 2016). Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. Translational Lung Cancer Research, 5 (6), 712-719. doi:10.21037/tlcr.2016.09.01
Peer Reviewed verified by ORBi

Romiti, A., Roberto, M., D'Antonio, C., ONESTI, C. E., Barucca, V., Milano, A., Gentile, G., Lionetto, L., Medda, E., Mazzuca, F., Botticelli, A., Falcone, R., Simmaco, M., & Marchetti, P. (November 2016). The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. Anti-Cancer Drugs, 27 (10), 1044-9. doi:10.1097/CAD.0000000000000429
Peer Reviewed verified by ORBi

Botticelli, A., Borro, M., ONESTI, C. E., Strigari, L., Gentile, G., Cerbelli, B., Romiti, A., Occhipinti, M., Sebastiani, C., Lionetto, L., Marchetti, L., Simmaco, M., Marchetti, P., & Mazzuca, F. (September 2016). Degradation rate of 5-fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker? PLoS ONE, 11 (9), 0163105. doi:10.1371/journal.pone.0163105
Peer Reviewed verified by ORBi

Roberto, M., Romiti, A., ONESTI, C. E., Zullo, A., Falcone, R., & Marchetti, P. (July 2016). Evolving treatments for advanced gastric cancer: appraisal of the survival trend. Expert Review of Anticancer Therapy, 16 (7), 717-29. doi:10.1080/14737140.2016.1184979
Peer Reviewed verified by ORBi

Roberto, M., Romiti, A., ONESTI, C. E., D'Antonio, C., Milano, A., Falcone, R., Barucca, V., Palombi, L., Righini, R., & Marchetti, P. (February 2016). A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anti-Cancer Drugs, 27 (2), 106-11. doi:10.1097/CAD.0000000000000308
Peer Reviewed verified by ORBi

ONESTI, C. E., Botticelli, A., Mazzuca, F., Milano, A., Romiti, A., Roberto, M., Falcone, R., Occhipinti, M., Di Pietro, F. R., Lionetto, L., Simmaco, M., & Marchetti, P. (2016). 5-fluorouracil degradation rate (5-FU-DR) as a new toxicity predictive biomarker for adjuvant FOLFOX in colorectal cancer (CRC) patients. Annals of Oncology, 27 (Suppl 6). doi:10.1093/annonc/mdw370.134
Peer Reviewed verified by ORBi

Roberto, M., Romiti, A., Pilozzi, E., Balducci, G., Ferri, M., Uccini, S., Falcone, R., Campisi, G., Mercantini, P., Mazzuca, F., Di Pietro, F. R., ONESTI, C. E., Botticelli, A., & Marchetti, P. (2016). Is the benefit of adjuvant chemotherapy limited to high risk stage II colorectal cancer ? Annals of Oncology. doi:10.1093/annonc/mdw335.24
Peer Reviewed verified by ORBi

ONESTI, C. E., Botticelli, A., Mazzuca, F., Angelini, S., Petremolo, A., Falcone, R., Roberto, M., Occhipinti, M., Romiti, A., Lionetto, L., Simmaco, M., & Marchetti, P. (2016). 5-fluorouracil degradation rate (5-FU-DR) could predict toxicity in breast cancer patients treated with capecitabine. Annals of Oncology, 27 (Suppl 4), 68. doi:10.1093/annonc/mdw337.29
Peer Reviewed verified by ORBi

Roberto, M., Romiti, A., Botticelli, A., Di Pietro, F. R., Lionetto, L., Gentile, G., Mazzuca, F., Falcone, R., Occhipinti, M., Macrini, S., Anselmi, E., Petremolo, A., ONESTI, C. E., Simmaco, M., & Marchetti, P. (2016). 5-fluorouracil degradation rate as a predictive toxicity biomarker in early stage gastrointestinal cancer. Annals of Oncology, 27 (Suppl 6). doi:10.1093/annonc/mdw363.48
Peer Reviewed verified by ORBi

ONESTI, C. E., Vicier, C., & André, F. (November 2015). What to expect from high throughput genomics in metastatic breast cancers? Breast, 24 (Suppl 2), 19-22. doi:10.1016/j.breast.2015.07.006
Peer reviewed

ONESTI, C. E., Romiti, A., Roberto, M., Falcone, R., & Marchetti, P. (September 2015). Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Review of Anticancer Therapy, 15 (10). doi:10.1586/14737140.2015.1081816
Peer Reviewed verified by ORBi

Di Girolamo, M., Paris, I., Carbonetti, F., ONESTI, C. E., Socciarelli, F., & Marchetti, P. (July 2015). Widespread renal polycystosis induced by crizotinib. Tumori Journal, 101 (4), 128-31. doi:10.5301/tj.5000338
Peer Reviewed verified by ORBi

Romiti, A., ONESTI, C. E., Roberto, M., Barucca, V., Tomao, S., D'Antonio, C., Durante, V., Milano, A., Falcone, R., Di Rocco, R., Righini, R., & Marchetti, P. (March 2015). Continous, low-dose capecitabine for patients with recurrent colorectal cancer. Medical Oncology, 32 (3), 54. doi:10.1007/s12032-015-0496-z
Peer Reviewed verified by ORBi

Roberto, M., Romiti, A., Lionetto, L., D'Antonio, C., ONESTI, C. E., Botticelli, A., Milano, A., Falcone, R., Occhipinti, M., Mazzuca, F., Simmaco, M., & Marchetti, P. (2015). 5-Fluorouracil degradation rate in patients with recurrent gastrointestinal cancer treated with metronomic capecitabine. Annals of Oncology, 27 (Suppl 2). doi:10.1093/annonc/mdw199.37
Peer Reviewed verified by ORBi

Deluche, E., ONESTI, C. E., & Andre, F. (2015). Precision medicine for metastatic breast cancer. American Society of Clinical Oncology Educational Book, 2-7. doi:10.14694/EdBook_AM.2015.35.e2
Peer Reviewed verified by ORBi

Lauro, S., Angelini, S., ONESTI, C. E., Occhipinti, M., Iacono, D., Righini, R., Giusti, R., Simmaco, M., & Marchetti, P. (2015). Genetic polymorphism can help physician choosing the best cancer chemotherapy. Annals of Oncology, 26 (Suppl 6), 84-vi85. doi:10.1093/annonc/mdv343.39
Peer Reviewed verified by ORBi

Lauro, S., Righini, R., ONESTI, C. E., Pucci, E., Bramini, A., & Marchetti, P. (December 2014). Gastric metastases from testicular cancer: case report and review of literature. Journal of Gastrointestinal Cancer, 45 (Suppl 1), 22-4. doi:10.1007/s12029-013-9524-4
Peer reviewed

Milano, A., Mazzetta, F., Raffa, S., Valente, S., Righini, R., ONESTI, C. E., Paris, I., Lauro, S., Torrisi, M. R., & Marchetti, P. (24 October 2014). Epithelial and mesenchimal molecular markers in circulating tumor cells (CTCs) from non-small cells lung cancer (NSCLC) patients [Poster presentation]. XVI Congresso Nazionale AIOM.

Roberto, M., D'Antonio, C., Romiti, A., Milano, A., Falcone, R., Durante, V., Mazzuca, F., ONESTI, C. E., Barucca, V., Righini, R., & Marchetti, P. (24 October 2014). Metronomic capecitabine in metastatic colorectal cancer: a phase II trial [Poster presentation]. XVI Congresso Nazionale AIOM.

D'Antonio, C., Milano, A., Righini, R., ONESTI, C. E., Bassanelli, M., Falcone, R., Paris, I., Lauro, S., & Marchetti, P. (October 2014). Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. Anticancer Research, 34 (10), 5241-50.
Peer Reviewed verified by ORBi

Lauro, S., ONESTI, C. E., Righini, R., & Marchetti, P. (April 2014). The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Research, 34 (4), 1537-45.
Peer Reviewed verified by ORBi

Lauro, S., ONESTI, C. E., Righini, R., Carbonetti, F., Cremona, A., & Marchetti, P. (2014). A Synchronous Pancreatic Metastasis from Renal Clear Cell Carcinoma, with Unusual CT Characteristics, Completely Regressed after Therapy with Sunitinib. Case Reports in Medicine, 473431. doi:10.1155/2014/473431
Peer Reviewed verified by ORBi

Paris, I., Prelaj, A., ONESTI, C. E., Baldoni, A., Giovagnoli, M. R., Bassanelli, M., Lauro, S., & Marchetti, P. (January 2014). Esophageal stenosis: a differential diagnosis between esophageal cancer and metastasis from other neoplasia. Anticancer Research, 34 (1), 363-66.
Peer Reviewed verified by ORBi

Carbonetti, F., ONESTI, C. E., Rampioni, G., Cremona, A., Lauro, S., Marchetti, P., & Mattei, M. (2014). Breast Metastasis of Thymic Carcinoma. British Journal of Medicine and Medical Research, 4 (24), 4178-85.
Peer Reviewed verified by ORBi

Lauro, S., ONESTI, C. E., Righini, R., D'Antonio, C., Simmaco, M., Zazzara, M. B., Bramini, A., & Marchetti, P. (2014). Relation between polymorphisms and chemotherapy in lung cancer. European Journal of Cancer, 50, 53-54.
Peer Reviewed verified by ORBi

D'Antonio, C., Romiti, A., Lombardini, A., Durante, V., Milano, A., Mazzuca, F., Sarcina, I., Falcone, R., ONESTI, C. E., Iacono, D., Righini, R., Palombi, L., & Marchetti, P. (11 October 2013). MTHFR C677T gene polymorphisms and susceptibility to cardiovascular adverse events in metastatic colorectal cancer treated with chemotherapy plus bevacizumab [Poster presentation]. XV Congresso Nazionale AIOM.

Vecchione, A., Belletti, B., Lovat, F., Volinia, S., Chiappetta, G., Giglio, S., Sonego, M., Cirombella, R., ONESTI, C. E., Pellegrini, P., Califano, D., Pignata, S., Losito, S., Canzonieri, V., Sorio, R., Alder, H., Wernicke, D., Stoppacciaro, A., Baldassarre, G., & Croce, C. M. (June 2013). A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 110 (24), 9845-50. doi:10.1073/pnas.1305472110
Peer Reviewed verified by ORBi

Contact ORBi